AU2014229476B2 - Antibodies to MICA and MICB proteins - Google Patents

Antibodies to MICA and MICB proteins Download PDF

Info

Publication number
AU2014229476B2
AU2014229476B2 AU2014229476A AU2014229476A AU2014229476B2 AU 2014229476 B2 AU2014229476 B2 AU 2014229476B2 AU 2014229476 A AU2014229476 A AU 2014229476A AU 2014229476 A AU2014229476 A AU 2014229476A AU 2014229476 B2 AU2014229476 B2 AU 2014229476B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
antibody
mica
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014229476A
Other languages
English (en)
Other versions
AU2014229476A1 (en
Inventor
Ian Wayne Cheney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novelogics Biotechnology Inc
Original Assignee
Novelogics Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novelogics Biotechnology Inc filed Critical Novelogics Biotechnology Inc
Publication of AU2014229476A1 publication Critical patent/AU2014229476A1/en
Application granted granted Critical
Publication of AU2014229476B2 publication Critical patent/AU2014229476B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2014229476A 2013-03-15 2014-03-15 Antibodies to MICA and MICB proteins Ceased AU2014229476B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361801329P 2013-03-15 2013-03-15
US61/801,329 2013-03-15
US201461940372P 2014-02-15 2014-02-15
US61/940,372 2014-02-15
PCT/IB2014/001157 WO2014140904A2 (en) 2013-03-15 2014-03-15 Antibodies to mica and micb proteins

Publications (2)

Publication Number Publication Date
AU2014229476A1 AU2014229476A1 (en) 2015-10-01
AU2014229476B2 true AU2014229476B2 (en) 2019-07-11

Family

ID=51538216

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014229476A Ceased AU2014229476B2 (en) 2013-03-15 2014-03-15 Antibodies to MICA and MICB proteins

Country Status (6)

Country Link
US (2) US10851148B2 (https=)
EP (1) EP2970490A4 (https=)
JP (2) JP6518199B6 (https=)
AU (1) AU2014229476B2 (https=)
CA (1) CA2906356A1 (https=)
WO (1) WO2014140904A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
CA2945822A1 (en) * 2014-05-21 2015-11-26 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
BR112017016681A2 (pt) 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
KR20180088458A (ko) * 2015-12-04 2018-08-03 다나-파버 캔서 인스티튜트 인크. 암의 치료를 위한 mica/b 알파 3 도메인의 백신접종
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
CA3040421A1 (en) * 2016-10-19 2018-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
CN107964041B (zh) * 2016-10-20 2023-08-01 中国科学院广州生物医药与健康研究院 高稳定性和高亲和力的dmic及其制法
EP3532091A2 (en) * 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
US20200023071A1 (en) 2017-02-06 2020-01-23 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
JP7458993B2 (ja) * 2018-01-25 2024-04-01 クリナン ミカ コーポレイション Ｍｉｃａ／ｂ抗体および使用方法
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
MX2021001254A (es) * 2018-07-31 2021-05-12 Cullinan Mica Corp Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso.
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
WO2020127965A1 (en) 2018-12-21 2020-06-25 Onxeo New conjugated nucleic acid molecules and their uses
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
AU2020336023A1 (en) * 2019-08-23 2022-03-03 Northwestern University Materials and methods for activating antigen-specific T cell responses
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
CN116547301A (zh) * 2020-08-10 2023-08-04 先天制药公司 使用抗体进行的细胞表面mica和micb检测
CN112574311B (zh) * 2020-12-14 2022-03-25 广州康盛生物科技股份有限公司 双mic结合活性的抗体及其应用
WO2022235676A1 (en) * 2021-05-04 2022-11-10 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer
JP2025500922A (ja) 2021-12-16 2025-01-15 ヴァレリオ・セラピューティクス 新規のコンジュゲートされた核酸分子及びその使用
JP2025512137A (ja) * 2022-04-08 2025-04-16 ディーツーエム バイオセラピューティクス リミテッド 抗ｍｉｃａ／ｂ抗体及びその使用
KR102783449B1 (ko) * 2022-06-15 2025-03-19 주식회사 셀리드 자연 살해 ｔ 세포의 리간드와 암 항원을 적재한 자연 살해 세포를 포함하는 백신

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2275141A1 (en) 1996-10-29 1998-05-07 Thomas Spies Cell stress regulated human mhc class i gene
CA2462790A1 (en) 2001-10-04 2003-04-10 Immunex Corporation Ul16 binding protein 4
AU2003225093A1 (en) 2002-04-22 2003-11-03 Fred Hutchinson Cancer Research Center Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
WO2005107802A2 (en) 2004-04-30 2005-11-17 Biopheresis Technologies, Llc Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
DE102004042894A1 (de) 2004-08-30 2006-03-02 Eberhard-Karls-Universität Tübingen Verwendung von Blockern der NKG2D-Rezeptor-/NKG2D-Liganden-Interaktion bei Autoimmunerkrankungen
CA2665090A1 (en) 2006-09-22 2008-03-27 Dana-Farber Cancer Institute, Inc. Methods for treating mica-related disorders
CA2685056C (en) 2007-04-23 2015-08-25 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by erp5
US8182809B1 (en) * 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
WO2010080124A2 (en) 2008-12-18 2010-07-15 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
TWI408370B (zh) 2011-05-19 2013-09-11 長庚大學 胰臟癌之血清生物檢測標誌及其應用
US8753640B2 (en) * 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
ES2925654T3 (es) 2011-09-30 2022-10-19 Dana Farber Cancer Inst Inc Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA)
EP2812027A1 (en) 2012-02-07 2014-12-17 Innate Pharma Mica binding agents
EP2626994B1 (en) 2012-02-08 2019-04-03 GE Oil & Gas UK Limited Supplying electrical power to subsea equipment
US20160030659A1 (en) 2013-03-15 2016-02-04 Novelogics Biotechnology, Inc. Methods and devices for removal of immunosuppressive ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Zou et al. "MICA is a target for Complement-Dependent Cytotoxicity with Mouse Monoclonal Antibodies and Human Alloantibodies", Human Immunology, 2002; v63, p30-39. *

Also Published As

Publication number Publication date
JP2016512223A (ja) 2016-04-25
AU2014229476A1 (en) 2015-10-01
JP6518199B6 (ja) 2019-06-12
JP2019194180A (ja) 2019-11-07
US20160046689A1 (en) 2016-02-18
EP2970490A4 (en) 2017-04-26
JP6518199B2 (ja) 2019-05-22
WO2014140904A2 (en) 2014-09-18
CA2906356A1 (en) 2014-09-18
US10851148B2 (en) 2020-12-01
US20210040173A1 (en) 2021-02-11
EP2970490A2 (en) 2016-01-20
WO2014140904A3 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
US20210040173A1 (en) Antibodies to mica and micb proteins
US11066471B2 (en) Antibodies to MICA and MICB proteins
US20250289880A1 (en) Use of anti-fam19a5 antibodies for treating cancers
US10675357B2 (en) Antibodies having specificity to nectin-4 and uses thereof
ES2742456T3 (es) Regímenes de tratamiento utilizando anticuerpos anti-NKG2A
US20180154064A1 (en) Methods and devices for removal of immunosuppressive ligands
KR20210015902A (ko) Psma 결합제 및 이의 용도
ES2984950T3 (es) Anticuerpos específicos para CD3 y sus usos
US20190062428A1 (en) Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
JP7716623B2 (ja) 排出ポンプ－癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
EP4291580A1 (en) Antibodies against cd112r and uses thereof
US20260028405A1 (en) Anti-cd16a antibodies and methods of use thereof
NZ751584A (en) Antibodies to mica and micb proteins
NZ751584B2 (en) Antibodies to mica and micb proteins
HK40046552B (zh) 对cd3特异性的抗体及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired